Suven Life Sciences Share Price: What Could the Next 3 Years Look Like?
- July 14, 2026
- Posted by: Ankit Jaiswal
- Category: News
Suven Life Sciences share price Rs 359 (10 July 2026). 52W high Rs 371, low Rs 124. Market cap Rs 10,144 Cr. 2030 scenario range Rs 445 to Rs 755.
The Suven Life Sciences share price forecast for the next 3 years is a question on many investors’ minds as the stock trades at Rs 359 on 10 July 2026, within a 52 week range of Rs 124 to Rs 371. This article lays out a scenario based Suven Life Sciences share price outlook for 2027, 2028 and 2030, built on the company’s fundamentals, sector trends and the key risks that could change the trajectory. Rather than a single number, the focus here is on the range of outcomes and the assumptions behind each one.
Click Here – Get Free Investment Predictions
Suven Life Sciences Company Overview
Suven Life Sciences is a clinical stage biopharmaceutical company developing novel therapies for central nervous system disorders such as Alzheimer’s, depression and sleep disorders, with several molecules in global clinical trials. Understanding the business model is the first step in framing any credible Suven Life Sciences share price forecast, because the durability of earnings ultimately decides where the stock trades.
| Company | Suven Life Sciences |
| NSE Ticker | SUVEN |
| CMP (10 July 2026) | Rs 359 |
| 52 Week High | Rs 371 |
| 52 Week Low | Rs 124 |
| Market Cap | Rs 10,144 Cr |
| Stock PE | NA |
| Book Value | Rs 22.4 |
| ROE | 78.8% |
| ROCE | 76.9% |
| Dividend Yield | 0% |
Where Does Suven Life Sciences Share Price Stand Today?
The stock currently trades about 3 percent below its 52 week high of Rs 371, which means the market has already tempered some of its optimism. For anyone building a Suven Life Sciences share price forecast, this correction matters for the Suven Life Sciences share price forecast starting point, because entry valuations have a large bearing on 3 year returns.
At the current price, Suven Life Sciences commands a market capitalisation of Rs 10,144 Cr and trades at a price to earnings multiple of NA. The company generates a return on equity of 78.8% and a return on capital employed of 76.9%, which places it in the category of businesses with strong return ratios. These numbers anchor the Suven Life Sciences share price forecast scenarios that follow. How the broader Nifty 50 index trades over this period will also influence the multiple investors are willing to assign to the stock.
Suven Life Sciences Share Price Forecast: Key Growth Drivers for the Next 3 Years
Four forces are likely to shape the Suven Life Sciences share price forecast between now and 2030, and together they explain most of the dispersion in this Suven Life Sciences share price forecast. Each is discussed below with its likely direction of impact.
Earnings Trajectory and Return Ratios
Stock prices ultimately follow earnings. With strong return ratios at present, the pace at which profits compound over FY27 to FY30 will be the single biggest determinant of the Suven Life Sciences share price forecast actually playing out. Consistent earnings delivery tends to expand valuation multiples, while misses compress them quickly.
Structural Tailwinds in Indian Pharmaceuticals
The Indian pharmaceutical market continues to grow in high single to low double digits, supported by chronic disease prevalence, better diagnosis rates and premiumisation of therapies. Companies with strong brand equity and field force productivity, like Suven Life Sciences, are positioned to grow ahead of the market. Sector trends are visible in the Nifty Pharma index, which serves as a useful barometer for the space.
Within the space, investors often benchmark Suven Life Sciences against peers such as Piramal Pharma, Divis Laboratories and Onesource Specialty Pharma on growth and valuations before forming a view on the Suven Life Sciences share price forecast.
Company Specific Catalysts
The bull case for Suven Life Sciences rests on positive clinical trial readouts for its CNS pipeline, potential licensing deals with global pharma majors and a debt free research focused balance sheet. If these play out on schedule, the Suven Life Sciences share price forecast for 2030 could gravitate toward the upper end of the scenario range discussed below.
Macro Environment and Liquidity
The RBI rate cycle, FII flows into Indian equities and overall market valuations will influence the multiple investors are willing to pay. A benign macro backdrop supports the optimistic end of any Suven Life Sciences share price forecast, while global risk aversion would do the opposite to the Suven Life Sciences share price outlook.
Suven Life Sciences Share Price Forecast 2027, 2028 and 2030: Scenario Analysis
The table below presents a scenario based Suven Life Sciences share price forecast using compounded annual growth assumptions applied to the current market price of Rs 359. These are illustrative ranges, not point predictions, and actual outcomes can fall outside them.
| Year | Bear Case | Base Case | Bull Case | Assumption |
|---|---|---|---|---|
| 2027 | Rs 385 | Rs 425 | Rs 460 | 5% to 18% CAGR on CMP |
| 2028 | Rs 405 | Rs 475 | Rs 545 | 5% to 18% CAGR on CMP |
| 2030 | Rs 445 | Rs 600 | Rs 755 | 5% to 18% CAGR on CMP |
In the base case scenario of this Suven Life Sciences share price forecast, the 2030 level works out to roughly Rs 600, implying steady compounding from today’s levels. The bull case of Rs 755 assumes positive clinical trial readouts for its CNS pipeline delivers ahead of expectations, while the bear case of Rs 445 captures a scenario where growth stalls. That is an outcome band of about 24 percent to 110 percent over the period.
Consult a SEBI Registered Investment Advisor Before Acting on Any Forecast
Bull Case vs Bear Case for Suven Life Sciences Share Price
The Bull Case
The optimistic Suven Life Sciences share price forecast assumes positive clinical trial readouts for its CNS pipeline, potential licensing deals with global pharma majors and a debt free research focused balance sheet. Combined with supportive sector conditions, this could lift both earnings and the valuation multiple, pushing the stock toward Rs 755 by 2030.
The Bear Case
The cautious view centres on the fact that the company is loss making with no commercial product yet, so trial failures or delays can sharply impact sentiment. If these pressures dominate, the Suven Life Sciences share price forecast would skew toward the lower band and the stock could stagnate near Rs 445 even by 2030, underperforming broader indices.
Key Risks That Could Change the Suven Life Sciences Share Price Outlook
- Execution risk: Delays in strategy execution or capacity plans would push the earnings trajectory below the base case assumed in this Suven Life Sciences share price forecast.
- Valuation risk: At a PE of NA, any earnings disappointment can trigger sharp multiple compression before fundamentals stabilise.
- Sector risk: The company is loss making with no commercial product yet, so trial failures or delays can sharply impact sentiment.
- Macro risk: A global slowdown, adverse FII flows or unexpected rate moves would compress equity valuations across the market.
- Regulatory risk: Policy, tax or compliance changes affecting the sector can alter the earnings outlook with little warning.
Is Suven Life Sciences Worth Watching for the Long Term?
For long term investors, the relevant question is not just where the Suven Life Sciences share price forecast lands in 2030 or what any single Suven Life Sciences share price forecast says today, but whether the business can compound capital through cycles. The company’s positioning around positive clinical trial readouts for its CNS pipeline gives it a credible growth story, while the risks outlined above define what must be monitored each quarter.
Investors should track quarterly earnings, management commentary and sector data rather than anchoring to any single number from a Suven Life Sciences share price outlook. Historically, staying focused on business fundamentals has served investors better than chasing price targets, and consulting a SEBI registered advisor before investing remains the prudent approach.
Download the Univest iOS App or Univest Android App to track Suven Life Sciences share price live.
Conclusion
The Suven Life Sciences share price forecast for the next 3 years spans Rs 445 to Rs 755 by 2030 under the scenarios discussed, with a base case near Rs 600. Any credible Suven Life Sciences share price forecast must be updated as facts change, and the path will be decided by earnings delivery, positive clinical trial readouts for its CNS pipeline and the broader market environment. Treat these ranges as a framework for thinking, not a promise of outcomes, and revisit the assumptions as new results come in. Consult a SEBI registered investment advisor before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What is the Suven Life Sciences share price forecast for the next 3 years?
Ans. The Suven Life Sciences share price forecast for the next 3 years is scenario based rather than a single number. By 2030, the illustrative range spans Rs 445 in the bear case to Rs 755 in the bull case, with a base case near Rs 600, depending on earnings delivery and market conditions.
What is the Suven Life Sciences share price forecast for 2027?
Ans. For 2027, the scenario range works out to Rs 385 to Rs 460, with a base case around Rs 425. This assumes compounding on the current price of Rs 359 and is illustrative, not a guaranteed outcome.
What is the Suven Life Sciences share price forecast for 2028?
Ans. The 2028 scenario range is Rs 405 to Rs 545, with the base case near Rs 475. Actual levels will depend on earnings growth, sector trends and overall market valuations at the time.
What is the current share price of Suven Life Sciences?
Ans. As of 10 July 2026, Suven Life Sciences trades at around Rs 359 on the NSE, within a 52 week range of Rs 124 to Rs 371. Prices change continuously during market hours, so check live quotes before acting.
Is Suven Life Sciences a good stock for the long term?
Ans. Suven Life Sciences has a credible long term story built on positive clinical trial readouts for its CNS pipeline, but it also carries risks since the company is loss making with no commercial product yet, so trial failures or delays can sharply impact sentiment. Long term suitability depends on your risk profile and portfolio, so consult a SEBI registered investment advisor before investing.
What is the Suven Life Sciences share price outlook for 2030?
Ans. The Suven Life Sciences share price outlook for 2030 spans Rs 445 to Rs 755 across bear and bull scenarios. Where the stock actually lands will be driven by profit growth, valuation multiples and macro conditions closer to that date.
What are the key risks to the Suven Life Sciences share price forecast?
Ans. The main risks are execution delays, valuation compression from the current PE of NA, sector specific pressures, macro shocks and regulatory changes. Any of these can push the stock below the base case scenario discussed in this article.
